
Episode 526: Global X ETFs Pedro Palandrani on the Global X NYSE 100 ETF & NYSE 100 Index
The Inside the Ice House podcast announced the launch of Global X’s NYSX ETF, which tracks the NYSE 100 index created in partnership with ICE and the New York Stock Exchange. The fund debuted on March 26 under the ticker NYSX and aims to give investors a rules‑based, passive exposure to the most innovative U.S. companies. NYSX targets the top 100 tech‑enabled growth firms listed on any major U.S. exchange. Selection follows a multi‑factor model—valuation, liquidity, size and growth—while the portfolio remains market‑cap weighted. At a 9‑basis‑point expense ratio, the ETF offers a low‑cost alternative to both broad market funds that dilute innovation exposure and narrow thematic ETFs that concentrate risk. Palandrani highlighted examples such as Tesla, a consumer‑discretionary name that drives AI and robotics, and emerging sectors like space exploration and defense technology. He emphasized the partnership with ICE, NYSE and parent company Mirae Asset, noting that the collaboration leveraged decades of thematic‑ETF expertise to craft a unique benchmark. For investors seeking targeted exposure to cross‑sector innovation, NYSX bridges the divide between overly broad index funds and highly concentrated thematic products. Its diversified yet focused composition and modest fee structure position it to capture growing demand for systematic, innovation‑centric allocation strategies.

Today on Taking Stock | S&P 500 HIts 7,100, Third Straight Record
The Friday closing bell on April 17 saw the S&P 500 break the 7,100 barrier for the first time, with the Dow up 1.8% and the Nasdaq and Russell 2000 also posting fresh all‑time highs. The rally was driven by...

Today on NYSE Live | Air Solutions Provider Madison Air Rings Opening Bell to Celebrate IPO on NYSE
Today's NYSE Live broadcast centered on Madison Air’s IPO celebration, highlighted by the company’s chief executive ringing the opening bell on International Women’s Day. The segment unfolded against a backdrop of the S&P 500 closing above the 7,000 mark for the...

The NYSE Welcomes Morgan Stanley Investment Management to Celebrate the Launch of MSBT (NYSE: MS)
Morgan Stanley Investment Management announced the launch of MSBT, the first spot Bitcoin exchange‑traded fund issued by a major U.S. bank, and was invited to the NYSE podium. The fund will trade under the ticker MS on the New York...

Today on Taking Stock | S&P 500 Notches Another Intraday All-Time High
U.S. equities pushed to fresh intraday records for a second consecutive day as the S&P 500 eyed another close above 7,000 and the Nasdaq also logged all-time highs, led by energy, telecom and technology names while healthcare, consumer discretionary and...

Nuvemshop CEO Santiago Sosa Says AI Is Core to the Latin American E-Commerce Co.
Nuvemshop’s co‑founder and CEO Santiago Sosa explained how artificial intelligence has become central to the Latin American e‑commerce platform’s strategy. The company, which began as a college‑time marketplace 15 years ago, now supports over 200,000 merchants and processes billions in gross merchandise...

Today on Taking Stock | S&P 500 Erases All Losses From U.S-Iran War
The S&P 500 rallied 1.1% to erase losses tied to the U.S.-Iran confrontation, marking nine wins in 10 sessions and leaving the index just shy of all-time highs. Tech and consumer discretionary led the advance with Amazon, Nvidia and Microsoft...

April Markets in Focus: Headline Driven Volatility, AI Impact, Long-Term Signals
The Inside the Ice House episode examined two intertwined forces shaping markets: the ongoing Middle East conflict and the rapid rise of AI‑driven research. Host Lance and market strategist Phil Rosen dissected how headline‑driven volatility can obscure longer‑term trends, using...

Today on Taking Stock | Investors Hold Out Hope for U.S.-Iran Peace Deal
Stocks rallied into the close on Monday as the S&P 500 finished up about 1% and the Russell 2000 led gains with a 1.5% advance, reversing early weakness. Tech, financials and telecoms outperformed while Goldman Sachs weighed on the Dow...

The Hill & Valley Forum: Sofreh Capital CEO Shervin Pishevar on Building Bridges
At the Hill & Valley Forum in Washington, D.C., Shervin Pishevar—founder and CEO of Freight Capital and former Uber board member—spoke about his two‑decade mission to connect Silicon Valley innovation with federal policy. He framed the gathering as a nexus...

Tom Hale CEO of ŌURA at HumanX
Oura CEO Tom Hale announced at HumanX the launch of the first‑ever dedicated women’s health model built into the Oura Ring, expanding the platform’s AI‑driven health coaching. The ring’s algorithms, based on machine‑learning models and neural networks, already translate finger‑based biometric...

Today on Taking Stock | S&P 500 Rises as Investors Monitor Geopolitics
U.S. equities cooled on Friday as the S&P 500 slipped about 0.1%, marking the first session in eight that failed to finish higher amid a late-cycle, defensive tone. Materials, tech and utilities outperformed while financials and healthcare lagged; mega-cap techs...

Eric Glyman, Co-Founder & CEO of Ramp at HumanX
In a recent HumanX interview, Eric Glyman, co‑founder and CEO of Ramp, outlined how the company’s AI‑powered financial platform is reshaping corporate spend management. Glyman said Ramp customers typically shave more than 5 % off annual expenses across cards, bill payments and...

Entière Dermatology Founder Dr Melissa Levin Dives Into Science of Sunscreen
The video features Dr. Melissa Levin, founder and medical director of Entière Dermatology, marking National Dermatologist Day by stressing sun‑safety and the science behind sunscreen. Levin explains that dermatology spans over 3,000 conditions, from inflammatory disorders to melanoma, and that an...

Enveda CEO Viswa Colluru on Positive Phase 1b Results for ENV 294 Therapy
Enveda’s chief executive, Viswa Colluru, highlighted the company’s AI‑powered chemistry platform that flips traditional drug discovery on its head by mining billions of years of natural molecular diversity. The approach underpinned the Phase 1b trial of ENV294, an oral tablet for moderate‑to‑severe...